Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma
New therapies have changed the outlook for patients with multiple myeloma, but novel agents are needed for patients who are refractory or relapsed on currently approved drug classes. Novel targets other than CD38 and BCMA are needed for new immunotherapy development, as resistance to daratumumab and...
Saved in:
Published in | Clinical cancer research Vol. 26; no. 22; pp. 6028 - 6038 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
15.11.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!